• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

MARGETUXIMAB Drug Record

  • Summary
  • Interactions
  • Claims
  • MARGETUXIMAB chembl:CHEMBL2364649 Antineoplastic

    Alternate Names:

    MARGETUXIMAB
    MGAH-22
    MGAH22

    Drug Info:

    FDA Approval not approved
    Drug Class monoclonal antibody
    Drug Indications antineoplastic agent
    (3 More Sources)

    Publications:

    Nordstrom JL et al., 2011, Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fcγ receptor binding properties., Breast Cancer Res
    Bang et al., 2017, First-in-human phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody, in patients with HER2-positive advanced solid tumors., Ann. Oncol.
  • MARGETUXIMAB   ERBB2

    Interaction Score: 1.26

    Interaction Types & Directionality:
    antibody (inhibitory)
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name MGAH22
    Novel drug target Established target
    Mechanism of Interaction Receptor protein-tyrosine kinase erbB-2 inhibitor

    PMIDs:
    22129105 28119295


    Sources:
    TdgClinicalTrial JAX-CKB ChemblInteractions TTD

  • MARGETUXIMAB   ERBB3

    Interaction Score: 1.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    ClearityFoundationClinicalTrial

  • TdgClinicalTrial: MGAH22

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications antineoplastic agent
    Drug Class monoclonal antibody
    FDA Approval not approved

    Publications:

  • TTD: MGAH22

    • Version: 2020.06.01

    Alternate Names:
    D0G5GB TTD Drug ID

    Drug Info:

    Publications:
    Nordstrom JL et al., 2011, Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fcγ receptor binding properties., Breast Cancer Res

  • JAX-CKB: MGAH22

    • Version: 27-September-2017

    Alternate Names:

    Drug Info:

    Publications:
    Bang et al., 2017, First-in-human phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody, in patients with HER2-positive advanced solid tumors., Ann. Oncol.

  • TTD: Margetuximab

    • Version: 2020.06.01

    Alternate Names:
    D01YYP TTD Drug ID

    Drug Info:

    Publications:

  • ChemblInteractions: CHEMBL2364649

    • Version: chembl_23

    Alternate Names:

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL2364649

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • ClearityFoundationClinicalTrial: MGAH22

    • Version: 15-June-2013

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21